FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review ...

Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...

(ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug ...

Tonix Pharmaceuticals was the most active symbol on Stocktwits before the bell on Wednesday as shares of the clinical-stage ...

Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a ...

We believe there is enormous opportunity for us in the animal pharmaceuticals market, as there is a significant need to deliver medications more efficiently,” Gelteq co-founder and CEO Nathan Givoni ...

Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective ...

LONDON - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the ...

According to a new study published in Nature Communications, researchers at the Department of Laboratory Medicine, Karolinska ...

accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the ...

The global market for Artificial Intelligence For Drug Development and Discovery Market has witnessed rapid growth, escalating from a valuation of $520 million in 2019 to a projected $4,815 million by ...

has accepted its supplemental New Drug Application (sNDA) for avatrombopag (DOPTELET ®) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune ...